MCID: RFR007
MIFTS: 26

Refractory Anemia with Excess Blasts in Transformation

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Refractory Anemia with Excess Blasts in Transformation

MalaCards integrated aliases for Refractory Anemia with Excess Blasts in Transformation:

Name: Refractory Anemia with Excess Blasts in Transformation 58 70
Raeb-T 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 D46.3
UMLS via Orphanet 71 C0002894 C0280028
Orphanet 58 ORPHA168960
UMLS 70 C0280028

Summaries for Refractory Anemia with Excess Blasts in Transformation

MalaCards based summary : Refractory Anemia with Excess Blasts in Transformation, also known as raeb-t, is related to myelodysplastic syndrome with excess blasts and refractory anemia. An important gene associated with Refractory Anemia with Excess Blasts in Transformation is CSF3 (Colony Stimulating Factor 3). The drugs Cytarabine and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and myeloid.

Related Diseases for Refractory Anemia with Excess Blasts in Transformation

Diseases related to Refractory Anemia with Excess Blasts in Transformation via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 23)
# Related Disease Score Top Affiliating Genes
1 myelodysplastic syndrome with excess blasts 10.8
2 refractory anemia 10.8
3 deficiency anemia 10.7
4 leukemia, acute myeloid 10.6
5 myelodysplastic syndrome 10.6
6 myeloid leukemia 10.6
7 leukemia 10.5
8 chromosomal triplication 10.4
9 acute promyelocytic leukemia 10.3
10 acute leukemia 10.3
11 pancytopenia 10.2
12 chromosome 5q deletion syndrome 9.9
13 aplastic anemia 9.9
14 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.9
15 mucositis 9.9
16 acute erythroid leukemia 9.9
17 rectum cancer 9.9
18 thrombophlebitis 9.9
19 mast-cell leukemia 9.9
20 acute myeloblastic leukemia without maturation 9.9
21 ring chromosome 1 9.9
22 ring chromosome 9.9
23 aregenerative anemia 9.9

Graphical network of the top 20 diseases related to Refractory Anemia with Excess Blasts in Transformation:



Diseases related to Refractory Anemia with Excess Blasts in Transformation

Symptoms & Phenotypes for Refractory Anemia with Excess Blasts in Transformation

Drugs & Therapeutics for Refractory Anemia with Excess Blasts in Transformation

Drugs for Refractory Anemia with Excess Blasts in Transformation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4 147-94-4 6253
2
Fludarabine Approved Phase 4 21679-14-1, 75607-67-9 30751
3
Etoposide Approved Phase 4 33419-42-0 36462
4
Idarubicin Approved Phase 4 58957-92-9 42890
5 Antibiotics, Antitubercular Phase 4
6 Anti-Infective Agents Phase 4
7 Immunosuppressive Agents Phase 4
8 Antiviral Agents Phase 4
9 Immunologic Factors Phase 4
10 Antimetabolites Phase 4
11 Anti-Bacterial Agents Phase 4
12 Etoposide phosphate Phase 4
13
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
15
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
16
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
17
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
18
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
19
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
20
Hydroxyurea Approved Phase 3 127-07-1 3657
21
Thioguanine Approved Phase 3 154-42-7 2723601
22
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
23
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
24
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
25
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
27
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
28
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
29
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
30
Daunorubicin Approved Phase 3 20830-81-3 30323
31
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
32
Molgramostim Investigational Phase 3 99283-10-0
33 Gemtuzumab Phase 3
34 Neuroprotective Agents Phase 2, Phase 3
35 Gastrointestinal Agents Phase 2, Phase 3
36 Methylprednisolone Acetate Phase 2, Phase 3
37 Antiemetics Phase 2, Phase 3
38 glucocorticoids Phase 2, Phase 3
39 Hormones Phase 2, Phase 3
40 Hormone Antagonists Phase 2, Phase 3
41 Antilymphocyte Serum Phase 2, Phase 3
42 Protective Agents Phase 2, Phase 3
43 Anti-Inflammatory Agents Phase 2, Phase 3
44 Analgesics Phase 3
45 Adjuvants, Immunologic Phase 3
46 Antineoplastic Agents, Hormonal Phase 3
47
asparaginase Phase 3
48 Hydrocortisone-17-butyrate Phase 3
49 Hydrocortisone hemisuccinate Phase 3
50 Hydrocortisone 17-butyrate 21-propionate Phase 3

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
2 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
3 A Randomised Study Comparing an Oral Regimen (Idarubicin and Etoposide) With an Intravenous Regimen (MAE) for Consolidation in Patients Over 55 Years With Acute Myeloid Leukaemia in First Complete Remission Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
4 Autologous Peripheral Blood Stem Cell Transplantation (PSCT) Versus a Second Intensive Consolidation Course After a Common Induction and Consolidation Course in Patients With Bad Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Secondary (SAML) to MDS of More Acute Than 6 Months Duration Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
5 Protocol for the Treatment of Adults Aged </= 60 Years With De Novo Acute Myeloblastic Leukaemia or Secondary AML or RAEB-T (AML 01/99 Trial) Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
6 Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
7 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
8 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
9 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
10 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
11 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
12 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
13 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
14 A Phase III Randomized Study Comparing Busulfan-Total Body Irradiation Versus Cyclophosphamide-Total Body Irradiation Preparative Regimen in Patients With Advanced Myelodysplastic Syndrome (MDS) or MDS-Related Acute Myeloid Leukemia (AML) Undergoing HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation, (A BMT Study) Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
15 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
16 Medical Research Council Working Party on Leukaemia in Childhood Acute Myeloid Leukaemia Trial 12 Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
17 A Randomized Multicenter Study of More Intensive Versus Less Intensive Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia (AML) or Transformed Refractory Anemia With Excess Blasts (RAEB-t). Terminated NCT00363025 Phase 3 Idarubicin versus daunorubicin
18 A Phase II Trial of Ethyol (Amifostine) in Adult Patients With Advanced Myelodysplastic Syndromes Unknown status NCT00003123 Phase 2 amifostine trihydrate
19 A Randomized Study Of The Safety And Efficacy Of Two Dose Schedules Of Gemcituzumab Ozogamicin In Patients With Intermediate-2 Or High-Risk Myelodysplastic Syndromes Unknown status NCT00022321 Phase 2 gemtuzumab ozogamicin
20 Treatment of Poor Risk Myelodysplasia With the Combination of Amifostine, Topotecan and ARA-C: A Phase II Study Unknown status NCT00003827 Phase 2 amifostine trihydrate;cytarabine;topotecan hydrochloride
21 Protocol for Treatment of Newly Diagnosed High Risk And Relapsed Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Ethyol and High-Dose Cytarabine + Mitoxantron Followed by Maintenance Phase Using Low-Dose ARA-C, rhGM-CSF, Pentoxifylline, Ciprofloxacin and Decadron Unknown status NCT00003407 Phase 2 amifostine trihydrate;cytarabine;mitoxantrone hydrochloride
22 Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen Completed NCT00365287 Phase 1, Phase 2 anti-thymocyte globulin;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
23 Safety and Efficacy Trial of Bevacizumab: Anti-VEGF Humanized Monoclonal Antibody (NSC 704865) Therapy for Myelodysplastic Syndrome (MDS) Completed NCT00022048 Phase 1, Phase 2
24 Gemtuzumab Ozogamicin (GO), Fludarabine, And Low-Dose TBI Followed By Donor Stem Cell Transplantation For Patients With Advanced Acute Myeloid Leukemia Or Myelodysplastic Syndrome Completed NCT00008151 Phase 2 cyclosporine;fludarabine phosphate;gemtuzumab ozogamicin;methotrexate;mycophenolate mofetil
25 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
26 Therapy of Myelodysplastic Syndrome (MDS) With Antithymocyte Globulin (ATG) and TNFR:Fc Completed NCT00005853 Phase 2
27 Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
28 Phase II Study With Decitabine (5-aza-2'-Deoxycytidine, DAC) in Myelodysplastic Syndromes Completed NCT00003361 Phase 2 decitabine
29 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With High Risk Hematologic Malignancies Completed NCT00003335 Phase 2 busulfan;cyclosporine;melphalan;methylprednisolone
30 Phase I/II Study of Combined Treatment With Amifostine (Ethyol) and Topotecan (Hycamtin MS) in Patients With Myelodysplastic Syndrome Completed NCT00003415 Phase 1, Phase 2 amifostine trihydrate;topotecan hydrochloride
31 PHASE II STUDY OF HIGH DOSE CYTARABINE COMBINED WITH A SINGLE HIGH DOSE OF IDARUBICIN FOR NEWLY DIAGNOSED PATIENTS WITH AML: THE AML-3 PROTOCOL Completed NCT00002800 Phase 2 cytarabine;etoposide;idarubicin
32 ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA Completed NCT00002547 Phase 2 busulfan;cyclophosphamide;cyclosporine;cytarabine;methotrexate
33 A Phase II Trial of Combination Therapy With Arsenic Trioxide (Trisenox) and Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Adult Patients With Advanced Myelodysplastic Syndrome Completed NCT00274781 Phase 2 arsenic trioxide;gemtuzumab ozogamicin
34 Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors Completed NCT00005622 Phase 2 cyclophosphamide
35 Allogeneic Peripheral Blood Stem Cell Transplantation Using a Non-Myeloablative Preparative Regimen for Patients With Hematologic Malignancies Completed NCT00004145 Phase 2 cyclophosphamide;fludarabine phosphate
36 A Multicenter Study of Unrelated Umbilical Cord Blood as an Alternate Source of Stem Cells for Transplantation Completed NCT00003913 Phase 2 busulfan;cyclophosphamide;methylprednisolone
37 Phase II Clinical Evaluation of Bryostatin 1 in Patients With Myelodysplastic Syndrome Completed NCT00003171 Phase 2 bryostatin 1
38 Use of G-CSF Stimulated HLA-Identical Allogeneic Peripheral Blood Stem Cells for Patients With High Risk Acute Myelogenous Leukemia or CML in Blast Crisis Completed NCT00002833 Phase 2 Cladribine;Cyclosporine;Cytarabine (Ara-C);Fludarabine Phosphate;Idarubicin;Methylprednisolone
39 Unrelated Bone Marrow Transplantation With Cyclophosphamide and Total Body Irradiation For Hematologic Malignancies and Bone Marrow Failure States Completed NCT00002809 Phase 2 cyclophosphamide;methotrexate;tacrolimus
40 Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation Completed NCT00055653 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;melphalan;methylprednisolone
41 A Pilot Study Of FR901228, Or Depsipeptide (NSC #630176) For Adult Patients With Advanced Hematologic Cancers Completed NCT00042822 Phase 2 romidepsin
42 A Phase II Study of the Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC #704865, IND # 7,921) Administered in Times Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Refractory and Relapsed Acute Myelogenous Leukemias (AMLs) Completed NCT00015951 Phase 2 cytarabine;mitoxantrone hydrochloride
43 Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies Completed NCT00014495 Phase 1, Phase 2 cytarabine
44 A Phase II Trial of IV Busulfan (Busulfex) and Melphalan as a Preparatory Regimen Prior to Allogeneic Bone Marrow Transplantation for the Treatment of Advanced and High Risk Hematologic Malignancies Completed NCT00014469 Phase 2 busulfan;melphalan;methotrexate;tacrolimus
45 Phase II Study of High-Dose Busulfan and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia Completed NCT00004896 Phase 2 busulfan;cyclophosphamide
46 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Children and Adults With Hematologic Malignancies Completed NCT00003661 Phase 2 busulfan;cyclosporine;melphalan;methylprednisolone
47 A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
48 Idarubicin and Ara-C in Combination With Gemtuzumab-Ozogamicin (IAGO) for Young Untreated Patients, Without an HLA Identical Sibling, With High Risk MDS or AML Developing After a Preceding Period With MDS During 6 Months Duration: A Phase II Study Completed NCT00077116 Phase 2 busulfan;cyclophosphamide;cytarabine;gemtuzumab ozogamicin;idarubicin
49 A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes Completed NCT00064376 Phase 2 paricalcitol
50 Hematopoietic Stem Cell Transplantation Using Bone Marrow Or Peripheral Blood Stem Cells From Matched, Unrelated, Volunteer Donors Completed NCT00054327 Phase 2 busulfan;cyclophosphamide;cytarabine;Etoposide

Search NIH Clinical Center for Refractory Anemia with Excess Blasts in Transformation

Genetic Tests for Refractory Anemia with Excess Blasts in Transformation

Anatomical Context for Refractory Anemia with Excess Blasts in Transformation

MalaCards organs/tissues related to Refractory Anemia with Excess Blasts in Transformation:

40
Bone Marrow, Bone, Myeloid, Endothelial, T Cells, Skin, Monocytes

Publications for Refractory Anemia with Excess Blasts in Transformation

Articles related to Refractory Anemia with Excess Blasts in Transformation:

(show top 50) (show all 571)
# Title Authors PMID Year
1
Impact of HFE gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes. 61
33791166 2021
2
Unmanipulated haploidentical hematopoietic stem cell transplantation for children with myelodysplastic syndrome. 61
32985788 2020
3
Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review. 61
30679915 2019
4
[Correlation of the Serum bFGF Level with MDS Typing, Serum IL-32 Level and Prognosis]. 61
30501708 2018
5
Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. 61
29433052 2018
6
A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). 61
28891083 2017
7
Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia. 61
27748021 2017
8
Treatment of Low-Blast Count AML using Hypomethylating Agents. 61
28698788 2017
9
Myelodysplastic and myeloproliferative disorders of childhood. 61
27913534 2016
10
Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome. 61
27013649 2016
11
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. 61
26968357 2016
12
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. 61
27084507 2016
13
Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 61
26799610 2016
14
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). 61
26400023 2015
15
Change of prognosis of patients with myelodysplastic syndromes during the last 30 years. 61
25929166 2015
16
Despite differential gene expression profiles pediatric MDS derived mesenchymal stromal cells display functionality in vitro. 61
25679997 2015
17
Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina. 61
25264233 2015
18
De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study. 61
25042343 2014
19
[The clinical analysis of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-identical siblings in 95 patients with myelodysplastic syndrome]. 61
24767157 2014
20
Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. 61
23790798 2013
21
The incidence of myelodysplastic syndromes in Western Greece is increasing. 61
23572136 2013
22
Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study. 61
22734597 2012
23
High frequency of human leukocyte antigen class II DRB1*1602 haplotype in Greek patients with myelodysplastic syndrome and of DRB1*1501 in the low-risk subgroup. 61
22244918 2012
24
Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis. 61
21967505 2012
25
Analysis of relative telomere length and apoptosis in humans exposed to ionising radiation. 61
22217714 2011
26
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. 61
21788559 2011
27
Advances in the prognostication and management of advanced MDS in children. 61
21554264 2011
28
Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children. 61
20813197 2011
29
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. 61
21212791 2011
30
Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. 61
21789382 2011
31
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. 61
20940414 2011
32
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. 61
20451404 2010
33
Epigenetic alterations of p15(INK4B) and p16(INK4A) genes in pediatric primary myelodysplastic syndrome. 61
20658957 2010
34
Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. 61
20578198 2010
35
Expression analysis of proteins involved in the non homologous end joining DNA repair mechanism, in the bone marrow of adult de novo myelodysplastic syndromes. 61
19727724 2010
36
[Analysis on laboratory and clinical characteristics in 65 cases of myelodysplastic syndrome]. 61
20030929 2009
37
[Serum proteomics in patients with RAEB myelodysplastic syndromes]. 61
19778794 2009
38
Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. 61
19589484 2009
39
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. 61
19638460 2009
40
Abnormal expression of C3ORF9 gene in patients with myelodysplastic syndromes. 61
19822096 2009
41
[Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases]. 61
19671296 2009
42
Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. 61
18829110 2009
43
Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children. 61
18951200 2008
44
Cytogenetic abnormalities in Tunisian de novo myelodysplastic syndrome: a comparison with other populations. 61
18556065 2008
45
Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. 61
18641985 2008
46
[Expressions of costimulatory molecules on CD3(+)CD4(+) T cells in myelodysplastic syndrome]. 61
18928600 2008
47
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. 61
18548095 2008
48
Detection of CD55- and CD59-deficient granulocytic populations in patients with myelodysplastic syndrome. 61
18158579 2008
49
[Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome]. 61
18247301 2008
50
Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes. 61
18417875 2008

Variations for Refractory Anemia with Excess Blasts in Transformation

Expression for Refractory Anemia with Excess Blasts in Transformation

Search GEO for disease gene expression data for Refractory Anemia with Excess Blasts in Transformation.

Pathways for Refractory Anemia with Excess Blasts in Transformation

GO Terms for Refractory Anemia with Excess Blasts in Transformation

Sources for Refractory Anemia with Excess Blasts in Transformation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....